Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Perrigo receives final approval from FDA for azelastine hydrochloride nasal spray ANDA

Perrigo Company plc announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%).

12 May 2014

GE Healthcare, Tesla Engineering announce collaboration to develop ultra high-field MRI systems

Today at the joint meeting of the International Society for Magnetic Resonance in Medicine and the European Society for Magnetic Resonance in Medicine and Biology, GE Healthcare and Tesla Engineering Ltd. announced that they will collaborate together to produce 7.0 tesla (7.0T) human whole-body magnetic resonance imaging (MRI) scanners, and build upon the ten year history of GE innovations in this advanced, technical field.

12 May 2014

EXCEMED meeting draws experts to explore roles of genetics, environment in MS pathology

The diagnosis and treatment of Multiple Sclerosis (MS) have dramatically improved over recent decades due to scientific advancements, yet MS persists as one of the most disabling neurological disorders, having a significant impact on young adults - the age group most affected by the disease.

9 May 2014

New study associates sex difference in brain with MS

A newly identified difference between the brains of women and men with multiple sclerosis (MS) may help explain why so many more women than men get the disease, researchers at Washington University School of Medicine in St. Louis report.

9 May 2014

Mice study shows specific energy source responsible for performing complex cognitive functions

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others.

9 May 2014

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.

9 May 2014

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

9 May 2014

Finding has implications for understanding cognitive decline in degenerative diseases

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others. The finding has implications for understanding the cognitive decline seen in aging and degenerative diseases such as Alzheimer's and multiple sclerosis.

8 May 2014

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

A drug typically prescribed for erectile dysfunction or increased pressure in the arteries may help improve blood flow in the muscles of boys with Duchenne muscular dystrophy, according to a study published in the May 7, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

8 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Calgary researcher receives $130,000 grant to develop clinical decision tools to aid epilepsy research

A researcher from the University of Calgary is receiving $130,000 to develop clinical decision tools to aid a physician's understanding of how a patient will respond to different treatments.

6 May 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from the Phase 3 ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) has been presented at the 66th American Academy of Neurology (AAN) annual meeting.

5 May 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

Study examines potential benefits of low fat diet on management of MS

People with multiple sclerosis who for one year followed a plant-based diet very low in saturated fat had much less MS-related fatigue at the end of that year - and significantly less fatigue than a control group of people with MS who didn't follow the diet, according to an Oregon Health & Science University study being presented today at the American Academy of Neurology's annual meeting in Philadelphia, Pa.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Genzyme, Cleveland Clinic partner to develop new therapeutic approaches for MS treatment

Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.

30 Apr 2014

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease.

29 Apr 2014

Highlights from April 2014 issue of Mayo Clinic Health Letter

Here are highlights from the April issue of Mayo Clinic Health Letter.

26 Apr 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

Noval neuroimaging technique enables detailed insights into mitochondria

Reactive oxygen species are important intracellular signaling molecules, but their mode of action is complex: In low concentrations they regulate key aspects of cellular function and behavior, while at high concentrations they can cause "oxidative stress", which damages organelles, membranes and DNA.

25 Apr 2014

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Perrigo receives final approval from FDA for azelastine hydrochloride nasal spray ANDA

GE Healthcare, Tesla Engineering announce collaboration to develop ultra high-field MRI systems

EXCEMED meeting draws experts to explore roles of genetics, environment in MS pathology

New study associates sex difference in brain with MS

Mice study shows specific energy source responsible for performing complex cognitive functions

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Finding has implications for understanding cognitive decline in degenerative diseases

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Calgary researcher receives $130,000 grant to develop clinical decision tools to aid epilepsy research

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Study examines potential benefits of low fat diet on management of MS

Biotech to the rescue

Genzyme, Cleveland Clinic partner to develop new therapeutic approaches for MS treatment

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

Highlights from April 2014 issue of Mayo Clinic Health Letter

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Noval neuroimaging technique enables detailed insights into mitochondria

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in